Recent studies of a relatively rare hereditary cancer syndrome, von Hippel-Lindau (VHL) disease, have shed new light on the molecular pathogenesis of kidney cancer and, perhaps more important, on how mammalian cells sense and respond to changes in oxygen availability. This knowledge is already translating into new therapeutic targets for kidney cancer as well as for multiple conditions, such as...

Mortality rates from kidney cancer increased throughout Europe up until the late 1980s or early 1990s. Trends in western European countries, the European Union (EU) and selected central and eastern European countries have been updated using official death certification data for kidney cancer abstracted from the World Health Organisation (WHO) database over the period 1980-1999. In EU men, death...

OBJECTIVES We examined the incidence trends of bladder and kidney cancers using a population-based cancer registration data. METHODS Age-standardized incidence rates were analyzed using data from the Shanghai Cancer Registry during 1973 to 2005. Annual percentage changes and 95% confidence intervals were calculated to evaluate the incidence changes. Age-period-cohort analysis was further impl...

Objective: Kidney transplantation is the best treatment option for patients with end-stage renal disease. However, transplant recipients have been shown to a higher risk of cancer than general population. This has attributed malignancies associated immunosuppression in these patients. In our study, we aimed investigate incidence post-transplant malignancy, duration development and factors kidne...

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a hereditary cancer syndrome in which affected individuals are at risk for development of cutaneous and uterine leiomyomas and an aggressive form of type II papillary kidney cancer. HLRCC is characterized by germline mutation of the tricarboxylic acid (TCA) cycle enzyme, fumarate hydratase (FH). FH-deficient kidney cancer is characte...

Sorafenib is an anticancer drug used to treat late stage kidney and liver cancer. advanced renal cell carcinoma (RCC; a type of cancer that begins in the kidneys). also hepatocellular (a cancer) cannot be treated with surgery certain thyroid has spread other parts body radioactive iodine. class medications called kinase inhibitors. It works by blocking action abnormal protein signals cells mult...

mTORC1 inhibitors were first approved for the use in metastatic kidney cancer. However, observed treatment benefit was highly heterogeneous among patients. Through case-based cancer genomic sequencing of therapeutic outliers, we can begin to appreciate the convergent evolution of given cancer pathways/phenotypes beyond genes in kidney cancer, like a braided river. Clin Cancer Res; 22(10); 2320-...

Kidney renal clear cell carcinoma (KIRC) is the predominant pathological subtype of kidney cancer and categorized as immunotherapy responsive. Hence, has become a worthwhile therapy for KIRC. Furthermore, tumor mutation burden (TMB) been regarded most prevalent biomarker to predict response. Accordingly, we spent effort characterize status predictive potential response gene mutations in In this...

Background Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) may play an important role in the outcome of kidney cancer patients. To explore the relationship between NOD2 and the prognosis of kidney cancer patients, a databank-based reanalysis was conducted. Materials and Methods Data related to kidney cancer patients at least with survival information, was obtained mainly...